NCT03769467 2024-11-14Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara BiotherapeuticsPhase 1/2 Terminated12 enrolled 8 charts
NCT05160168 2024-06-05A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Theseus PharmaceuticalsPhase 1/2 Terminated32 enrolled 20 charts
NCT01234480 2023-05-16Intended Use Study of the BD SurePath Plusâ„¢ PapBecton, Dickinson and CompanyTerminated5,859 enrolled 4 charts
NCT02592876 2019-05-17Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaSeagen Inc.Phase 2 Terminated81 enrolled 15 charts
NCT02855359 2019-03-11Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaSeagen Inc.Phase 2 Terminated24 enrolled 10 charts
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts
NCT00365274 2014-06-02SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaNational Cancer Institute (NCI)Phase 2 Terminated6 enrolled 3 charts